News — ROCHESTER, Minnesota — researchers have identified a potential new way to monitor the progression of high-grade , one of the most aggressive types of . Their feasibility study suggests that a personalized blood test tailored to each patient's tumor DNA could provide a faster and less invasive way to determine if the cancer is advancing.
Currently, clinicians rely on scans and surgical biopsies to monitor gliomas, but both methods have limitations. For example, scans often cannot distinguish tumor growth from treatment effects such as inflammation. Biopsies require invasive procedures, making them impractical for routine monitoring.
This new approach, , may provide clinicians with another tool to monitor tumor changes over time and adjust treatment as needed.
The findings focus on tumor DNA fragments circulating in the blood. As gliomas grow, some glioma cells die, shedding pieces of their DNA into the bloodstream and leaving behind genetic markers that are unique to the tumor.
However, gliomas release fewer DNA fragments into the blood compared to many other cancers. This is because of the blood-brain barrier, a natural brain defense that prevents many substances from leaving the brain.
To overcome this limitation, researchers focused on DNA junctions, a type of tumor-specific DNA fragment that is present in higher quantities. By targeting these markers, researchers achieved greater sensitivity, enabling them to detect even the smallest signs of tumor progression.
Unlike normal DNA, which follows a structured sequence, these DNA junctions form when the tumor's genetic material breaks and rearranges. The study found that these amplified DNA junctions, due to their higher numbers, may provide a clearer picture of disease progression.
"This research builds on years of studying genetic rearrangements and gives us a deeper understanding of the molecular mechanisms driving gliomas," says lead author , co-director of the Biomarker Discovery Program at and . "It offers new possibilities for patient-specific monitoring and targeted interventions."
In the study, researchers analyzed samples from patients with high-grade gliomas. They used whole genome sequencing to map each tumor's unique genetic blueprint and pinpointed patient-specific DNA junctions. Researchers then developed personalized blood tests to search for these genetic markers in plasma.
The test detected tumor DNA in approximately 93% of the cases where these DNA junctions were present. In some patients, tumor DNA levels in the blood rose before MRI scans showed any changes — offering a potential early signal for disease progression.
Connecting cutting-edge research and clinical practice, Dr. Vasmatzis and , a at Mayo Clinic in Rochester, Minnesota, collaborated on the research.
"By tracking each tumor's distinct molecular signature, we're aiming to shift from a reactive approach to one that's far more proactive," says Dr. Burns, a study co-author. "This research could lay the groundwork for tools that help clinicians make the most informed treatment decisions as early as possible."
Future studies will evaluate how well blood-based tumor tracking correlates with glioma progression across a larger group of patients.
Review the for a complete list of authors, disclosures and funding.
###
About Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the for additional Mayo Clinic news.
Media contact:
- Susan Murphy, Mayo Clinic Communications, [email protected]
RSS